<DOC>
	<DOCNO>NCT00003963</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness monoclonal antibody rituximab plus chemotherapy vinorelbine treat patient B-cell non-Hodgkin 's lymphoma relapse follow autologous peripheral stem cell transplantation .</brief_summary>
	<brief_title>Chemotherapy Monoclonal Antibody Therapy Treating Patients With B-cell Non-Hodgkin 's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : - Determine tolerability toxicity rituximab combine vinorelbine patient relapse non-Hodgkin 's lymphoma follow autologous peripheral blood stem cell transplantation . - Assess response rate duration response regimen patient . OUTLINE : Patients receive rituximab IV weekly week 1-4 , 6 , 8 , 10 , 12 vinorelbine IV week 2-4 , 6-8 , 10-12 . Patients achieve partial response may continue vinorelbine week 14 disease progression . Patients follow disease progression . PROJECTED ACCRUAL : A total 18-25 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Patients Bcell Lymphoma , relapse high dose chemotherapy autologous stem cell transplantation allogeneneic stem cell bone marrow transplant Age &gt; 18 year old Adequate hematologic function , manifest ANC &gt; 1000/mm3 platelet count &gt; 40,000/mm3 PS WHO : &lt; 3 Patients serum creatinine &gt; 2 mg % , transaminase ( ALT , AST ) &gt; 3 time upper normal value , direct bilirubin &gt; 2 mg % , unless result tumor involvement Pregnant lactating female History myelodysplastic syndrome Uncontrolled CNS disease Active serious infection History refractoriness vinorelbine . However , prior treatment rituxan exclusion ( synergy may still occur )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>